238 related articles for article (PubMed ID: 23847615)
1. Re-Directing CD4(+) T Cell Responses with the Flanking Residues of MHC Class II-Bound Peptides: The Core is Not Enough.
Holland CJ; Cole DK; Godkin A
Front Immunol; 2013; 4():172. PubMed ID: 23847615
[TBL] [Abstract][Full Text] [Related]
2. Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide-MHC Class II Multimers.
Holland CJ; Dolton G; Scurr M; Ladell K; Schauenburg AJ; Miners K; Madura F; Sewell AK; Price DA; Cole DK; Godkin AJ
J Immunol; 2015 Dec; 195(12):5827-36. PubMed ID: 26553072
[TBL] [Abstract][Full Text] [Related]
3. Structural and biophysical insights into the role of CD4 and CD8 in T cell activation.
Li Y; Yin Y; Mariuzza RA
Front Immunol; 2013; 4():206. PubMed ID: 23885256
[TBL] [Abstract][Full Text] [Related]
4. Naturally processed HLA class II peptides reveal highly conserved immunogenic flanking region sequence preferences that reflect antigen processing rather than peptide-MHC interactions.
Godkin AJ; Smith KJ; Willis A; Tejada-Simon MV; Zhang J; Elliott T; Hill AV
J Immunol; 2001 Jun; 166(11):6720-7. PubMed ID: 11359828
[TBL] [Abstract][Full Text] [Related]
5. Recognition of core and flanking amino acids of MHC class II-bound peptides by the T cell receptor.
Sant'Angelo DB; Robinson E; Janeway CA; Denzin LK
Eur J Immunol; 2002 Sep; 32(9):2510-20. PubMed ID: 12207335
[TBL] [Abstract][Full Text] [Related]
6. MPID-T: database for sequence-structure-function information on T-cell receptor/peptide/MHC interactions.
Tong JC; Kong L; Tan TW; Ranganathan S
Appl Bioinformatics; 2006; 5(2):111-4. PubMed ID: 16722775
[TBL] [Abstract][Full Text] [Related]
7. T cell receptor recognition of MHC class II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage.
Carson RT; Vignali KM; Woodland DL; Vignali DA
Immunity; 1997 Sep; 7(3):387-99. PubMed ID: 9324359
[TBL] [Abstract][Full Text] [Related]
8. Force-Regulated In Situ TCR-Peptide-Bound MHC Class II Kinetics Determine Functions of CD4+ T Cells.
Hong J; Persaud SP; Horvath S; Allen PM; Evavold BD; Zhu C
J Immunol; 2015 Oct; 195(8):3557-64. PubMed ID: 26336148
[TBL] [Abstract][Full Text] [Related]
9. Human leukocyte antigen (HLA) class II peptide flanking residues tune the immunogenicity of a human tumor-derived epitope.
MacLachlan BJ; Dolton G; Papakyriakou A; Greenshields-Watson A; Mason GH; Schauenburg A; Besneux M; Szomolay B; Elliott T; Sewell AK; Gallimore A; Rizkallah P; Cole DK; Godkin A
J Biol Chem; 2019 Dec; 294(52):20246-20258. PubMed ID: 31619516
[TBL] [Abstract][Full Text] [Related]
10. The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues.
Arnold PY; La Gruta NL; Miller T; Vignali KM; Adams PS; Woodland DL; Vignali DA
J Immunol; 2002 Jul; 169(2):739-49. PubMed ID: 12097376
[TBL] [Abstract][Full Text] [Related]
11. Modeling alternative binding registers of a minimal immunogenic peptide on two class II major histocompatibility complex (MHC II) molecules predicts polarized T-cell receptor (TCR) contact positions.
Murray JS; Fois SD; Schountz T; Ford SR; Tawde MD; Brown JC; Siahaan TJ
J Pept Res; 2002 Mar; 59(3):115-22. PubMed ID: 11985705
[TBL] [Abstract][Full Text] [Related]
12. Modification of the carboxy-terminal flanking region of a universal influenza epitope alters CD4⁺ T-cell repertoire selection.
Cole DK; Gallagher K; Lemercier B; Holland CJ; Junaid S; Hindley JP; Wynn KK; Gostick E; Sewell AK; Gallimore AM; Ladell K; Price DA; Gougeon ML; Godkin A
Nat Commun; 2012 Feb; 3():665. PubMed ID: 22314361
[TBL] [Abstract][Full Text] [Related]
13. The Role of Molecular Flexibility in Antigen Presentation and T Cell Receptor-Mediated Signaling.
Natarajan K; Jiang J; May NA; Mage MG; Boyd LF; McShan AC; Sgourakis NG; Bax A; Margulies DH
Front Immunol; 2018; 9():1657. PubMed ID: 30065727
[TBL] [Abstract][Full Text] [Related]
14. MHC Molecules, T cell Receptors, Natural Killer Cell Receptors, and Viral Immunoevasins-Key Elements of Adaptive and Innate Immunity.
Jiang J; Natarajan K; Margulies DH
Adv Exp Med Biol; 2019; 1172():21-62. PubMed ID: 31628650
[TBL] [Abstract][Full Text] [Related]
15. Major histocompatibility complex (MHC) class II-peptide complexes arrive at the plasma membrane in cholesterol-rich microclusters.
Bosch B; Heipertz EL; Drake JR; Roche PA
J Biol Chem; 2013 May; 288(19):13236-42. PubMed ID: 23532855
[TBL] [Abstract][Full Text] [Related]
16. Structural Comparison Between MHC Classes I and II; in Evolution, a Class-II-Like Molecule Probably Came First.
Wu Y; Zhang N; Hashimoto K; Xia C; Dijkstra JM
Front Immunol; 2021; 12():621153. PubMed ID: 34194421
[TBL] [Abstract][Full Text] [Related]
17. PANDORA v2.0: Benchmarking peptide-MHC II models and software improvements.
Parizi FM; Marzella DF; Ramakrishnan G; 't Hoen PAC; Karimi-Jafari MH; Xue LC
Front Immunol; 2023; 14():1285899. PubMed ID: 38143769
[TBL] [Abstract][Full Text] [Related]
18. Constraints within major histocompatibility complex class I restricted peptides: presentation and consequences for T-cell recognition.
Theodossis A; Guillonneau C; Welland A; Ely LK; Clements CS; Williamson NA; Webb AI; Wilce JA; Mulder RJ; Dunstone MA; Doherty PC; McCluskey J; Purcell AW; Turner SJ; Rossjohn J
Proc Natl Acad Sci U S A; 2010 Mar; 107(12):5534-9. PubMed ID: 20212169
[TBL] [Abstract][Full Text] [Related]
19. Functional evidence for TCR-intrinsic specificity for MHCII.
Parrish HL; Deshpande NR; Vasic J; Kuhns MS
Proc Natl Acad Sci U S A; 2016 Mar; 113(11):3000-5. PubMed ID: 26831112
[TBL] [Abstract][Full Text] [Related]
20. 3-Layer-based analysis of peptide-MHC interaction: in silico prediction, peptide binding affinity and T cell activation in a relevant allergen-specific model.
Knapp B; Omasits U; Bohle B; Maillere B; Ebner C; Schreiner W; Jahn-Schmid B
Mol Immunol; 2009 May; 46(8-9):1839-44. PubMed ID: 19232439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
